Zetomipzomib

DB16070InvestigationalSmall molecule

Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).

Mechanism: Pharmacologically active on Proteasome subunit beta type-8
Curator reviewed
Formula / weight: C₃₀H₄₂N₄O₈ · 586.686 g/mol (avg)
Also known as: (2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide
Code names: KZR-616

Resolves to

Compound

UNIIO4BT6C02M2CAS1629677-75-3ChEMBLCHEMBL4297468

Structure

InChIKeyGHYOCDFICYLMRF-UTIIJYGPSA-NSMILESCOC1=CC=C(C=C1)[C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CCCC1)C(=O)[C@@]1(C)CO1

Targets

P28062PSMB8

What you can answer from here — as of October 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zetomipzomib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account